Clinical trials: Alteplase
Stroke
A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30…
- Trial name
- ORIGINAL (NCT04915729)
- Testing
- tenecteplase, alteplase
- Where
- 55 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Boehringer Ingelheim
Stroke
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5…
- Trial name
- NCT05395351
- Testing
- rt-PA
- Where
- China
- Volunteers
- 113,035 people
- Sponsor
- Boehringer Ingelheim
Plastic Bronchitis, Protein-Losing Enteropathies
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic bronchitis (PB) is a rare, most often pediatric disease characterized by the formation of obstructive airway casts primarily composed of fibrin.
- Conditions
- Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
- Trial name
- PLATyPuS (NCT02315898)
- Testing
- Treatment-inhaled tPA
- Where
- 6 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Catheter Obstruction, Vascular Access Devices
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD
- Trial name
- NCT01958164
- Testing
- Actilyse, Saline solution
- Where
- 5 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Stroke
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
To evaluate the safety and efficacy of alteplase when administered between 3 and 4.5 hours after onset of stroke symptoms in Chinese patients with acute ischemic stroke
- Trial name
- NCT02930837
- Testing
- alteplase
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Compare 2 Different Formulations of Alteplase
To establish the bioequivalence of alteplase derived from two different manufacturing processes.
- Trial name
- NCT04419493
- Testing
- Alteplase (from modified manufacturing process), Alteplase (from current manufacturing process), Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Pleural Empyema
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Bacterial pneumonia can be complicated by the development of excess fluid and pus (pleural empyema) around the lungs in children. The incidence of pleural empyema in children has increased significantly in the last 10 years.
- Trial name
- NCT01717742
- Testing
- TPA (Tissue Plasminogen Activator), DNase
- Where
- 6 sites in Canada
- Volunteers
- 97 people
- Sponsor
- The Hospital for Sick Children
Ischemic Stroke
Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban…
- Trial name
- ARTSS-2 (NCT01464788)
- Testing
- Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew D. Barreto, MD
Abdominal Abscess, Pelvic Abscess
Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.
- Trial name
- NCT00284739
- Testing
- Alteplase, saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kaiser Permanente
Ischemic Stroke
Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery
To assess the safety and preliminary efficacy of combining intravenous rt-PA with transcranial laser therapy (TLT) with the NeuroThera® Laser System (referred to hereafter as NTS) in subjects treated for acute ischemic stroke.
- Trial name
- StELLAR (NCT01220739)
- Testing
- Transcranial Laser Therapy
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection
The purpose of this pilot study is to test feasibility of concept, consent and enrollment rates, and mechanics of study designed to assess if intra-catheter dwells of tissue plasminogen activator (t-PA) is effective in decreasing…
- Trial name
- TOPCAT (NCT03672006)
- Testing
- alteplase (recombinant t-PA), Heparin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
COVID
Nebulised Rt-PA for ARDS Due to COVID-19
Some patients infected with COVID-19 develop a severe form of a lung disease called acute respiratory distress syndrome (ARDS). In these patients, the lungs become severely inflamed because of the virus.
- Trial name
- PACA (NCT04356833)
- Testing
- Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University College, London
Acute Deep Venous Thrombosis of the Lower Extremity
Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
This study will test the effectiveness of low-dose recombinant tissue plasminogen activator (rtPA, or alteplase) in dissolving blood clots in deep leg veins.
- Trial name
- NCT00082355
- Testing
- Alteplase (Activase, Genentech)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Richard Chang, M.D.
Short Bowel Syndrome
rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome
The primary research question is, in patients with short bowel syndrome requiring central venous access device (CVAD) for long-term total parenteral nutrition, is once weekly recombinant tissue plasminogen activator (rtPA) lock…
- Trial name
- NCT02355743
- Testing
- rtPA lock therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Lynn Malec
Intraventricular Hemorrhage
Clinical Trial on Treatment of Intraventricular Hemorrhage
The specific objective of this trial is to determine the lowest dose and dose frequency possible with the best pharmacokinetic and safety profile and it's ability to remove a blood clot from the ventricular system.
- Trial name
- CLEAR IVH (NCT00650858)
- Testing
- tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
- Where
- 25 sites in United States, Canada and 2 more
- Volunteers
- 52 people
- Sponsor
- Johns Hopkins University
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Deep Vein Thrombosis, Venous Thrombosis
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic…
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism
- Trial name
- ATTRACT (NCT00790335)
- Testing
- Recombinant tissue plasminogen activator (rt-PA)
- Where
- 56 sites in United States
- Volunteers
- 692 people
- Sponsor
- Washington University School of Medicine
Stroke
Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator…
- Trial name
- NCT00252239
- Testing
- tenecteplase, tissue plasminogen activator, tPA
- Where
- 9 sites in United States
- Volunteers
- 112 people
- Sponsor
- University of Virginia
Stroke
Interventional Management of Stroke (IMS) III Trial
The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.
- Trial name
- IMSIII (NCT00359424)
- Testing
- IV rt-PA alone, endovascular therapy
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 656 people
- Sponsor
- Joseph Broderick